Korean J Gastroenterol.  2024 Aug;84(2):43-50. 10.4166/kjg.2024.070.

Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins

• Kim KO
• Lee SH

• KMID: 2558902
• DOI: http://doi.org/10.4166/kjg.2024.070

Abstract

Recently, novel biologics or small molecular drugs have been introduced for overcoming the unmet needs associated with anti-tumor necrosis factor α agents for inflammtory bowel disease (IBD) treatment. Among these novel drugs, anti integrin agents block leukocyte trafficking to the intestine by blocking the interaction between integrin and cell adhesion molecules. Vedolizumab (anti-α4β7) is most widely used anti-integrin approved in both ulcerative colitis and Crohn’s disease .It has been shown to be effective in both induction and maintenance therapy with a favorable safety profile due to gut selectivity. Several models incorporating clinical, genetic, immune and gut microbial markers to predict response to vedolizumab in IBD have been developed. Etrolizumab (anti-β7) blocks leukocyte trafficking via α4β7 and cell adhesion via αEβ7 integrins. In addition, the introduction of subcutaneous vedolizumab showed similar efficacy and safety with improved patients’ convenience. Other investigational anti-integrin therapies include abrilumab (anti-α4β7 IgG2), PN-943 (orally administered and gut-restricted α4β7 antagonist peptide), AJM300 (orally active small molecule inhibitor of α4), and ontamalimab (anti-MAdCAM-1 IgG).

Keyword

Integrin; Inflammatory bowel disease; Vedolizumab; Natalizumab; Etrolizumab

Reference

1. Atreya R, Neurath MF. IBD pathogenesis in 2014: molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol. 2015; 12:67–68. DOI: 10.1038/nrgastro.2014.201. PMID: 25446731.

2. Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. 2015; The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther. 149:191–212. DOI: 10.1016/j.pharmthera.2014.12.006. PMID: 25561343.

3. de Souza HS, Fiocchi C. 2016; Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 13:13–27. DOI: 10.1038/nrgastro.2015.186. PMID: 26627550.

4. Sokol H, Seksik P, Cosnes J. 2014; Complications and surgery in the inflammatory bowel diseases biological era. Curr Opin Gastroenterol. 30:378–384. DOI: 10.1097/MOG.0000000000000078. PMID: 24840000.

5. Im JP, Ye BD, Kim YS, Kim JS. 2018; Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med. 33:28–35. DOI: 10.3904/kjim.2017.400. PMID: 29334728. PMCID: PMC5768555.

6. Jung YS, Han M, Park S, Cheon JH. 2020; Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study. Korean J Intern Med. 35:1104–1113. DOI: 10.3904/kjim.2020.001. PMID: 32306709. PMCID: PMC7487310.

7. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. 2015; selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 110:1324–1338. DOI: 10.1038/ajg.2015.233. PMID: 26303131.

8. Roda G, Jharap B, Neeraj N, Colombel JF. 2016; Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 7:e135. DOI: 10.1038/ctg.2015.63. PMID: 26741065. PMCID: PMC4737871.

9. Hong SW, Park J, Yoon H, et al. 2021; Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease. Korean J Intern Med. 36(Suppl 1):S9–S17. DOI: 10.3904/kjim.2019.279. PMID: 32580540. PMCID: PMC8009168.

10. Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P. on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. 2020; TNF-alpha blockers in inflammatory bowel diseases: practical recommendations and a user's guide: an update. Digestion. 101 Suppl 1:16–26. DOI: 10.1159/000506898. PMID: 32739923.

11. Choi SJ, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. 2020; Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study. Korean J Intern Med. 35:723–731. DOI: 10.3904/kjim.2018.407. PMID: 31870134. PMCID: PMC7214361.

12. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. 2007; Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 7:678–689. DOI: 10.1038/nri2156. PMID: 17717539.

13. Binion DG, West GA, Ina K, Ziats NP, Emancipator SN, Fiocchi C. 1997; Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 112:1895–1907. DOI: 10.1053/gast.1997.v112.pm9178682. PMID: 9178682.

14. Danese S, Panés J. 2014; Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 147:981–989. DOI: 10.1053/j.gastro.2014.08.044. PMID: 25220794.

15. Sandborn WJ, Colombel JF, Enns R, et al. 2005; Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 353:1912–1925. DOI: 10.1056/NEJMoa043335. PMID: 16267322.

16. Targan SR, Feagan BG, Fedorak RN, et al. 2007; Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology. 132:1672–1683. DOI: 10.1053/j.gastro.2007.03.024. PMID: 17484865.

17. Feagan BG, Rutgeerts P, Sands BE, et al. 2013; Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 369:699–710. DOI: 10.1056/NEJMoa1215734. PMID: 23964932.

18. Sandborn WJ, Feagan BG, Rutgeerts P, et al. 2013; Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 369:711–721. DOI: 10.1056/NEJMoa1215739. PMID: 23964933.

19. Sands BE, Feagan BG, Rutgeerts P, et al. 2014; Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 147:618–627.e3. DOI: 10.1053/j.gastro.2014.05.008. PMID: 24859203.

20. Rubin DT, Dotan I, DuVall A, et al. 2022; Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 7:17–27. DOI: 10.1016/S2468-1253(21)00338-1. PMID: 34798036.

21. Peyrin-Biroulet L, Hart A, Bossuyt P, et al. 2022; Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 7:128–140. DOI: 10.1016/S2468-1253(21)00298-3. PMID: 34798039.

22. Sandborn WJ, Panes J, Jones J, Hassanali A, Jacob R, Sharafali Z. 2017; LB03 Etrolizumab as induction therapy in moderate to severe Crohn's disease: results from Bergamot cohort 1. United European Gastroenterol J. 5:1138–1150.

23. Vermeire S, Sandborn WJ, Danese S, et al. 2017; Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 390:135–144. DOI: 10.1016/S0140-6736(17)30930-3. PMID: 28527704.

24. Reinisch W, Sandborn WJ, Danese S, et al. 2021; Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab [SHP647] for the treatment of ulcerative colitis: the open-label study TURANDOT II. J Crohns Colitis. 15:938–949. DOI: 10.1093/ecco-jcc/jjab023. PMID: 33599720. PMCID: PMC8218706.

25. Sandborn WJ, Lee SD, Tarabar D, et al. 2018; Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 67:1824–1835. DOI: 10.1136/gutjnl-2016-313457. PMID: 28982740. PMCID: PMC6145284.

26. Sandborn WJ, Cyrille M, Hansen MB, et al. 2019; Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology. 156:946–957.e18. DOI: 10.1053/j.gastro.2018.11.035. PMID: 30472236.

27. Modi NB, Cheng X, Mattheakis L, et al. 2021; Single- and multiple-dose pharmacokinetics and pharmacodynamics of PN-943, a gastrointestinal-restricted oral peptide antagonist of α4β7, in healthy volunteers. Clin Pharmacol Drug Dev. 10:1263–1278. DOI: 10.1002/cpdd.946. PMID: 33942566. PMCID: PMC8597174.

28. Matsuoka K, Watanabe M, Ohmori T, et al. 2022; AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 7:648–657. DOI: 10.1016/S2468-1253(22)00022-X. PMID: 35366419.

29. Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. 2014; Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 39:579–594. DOI: 10.1111/apt.12639. PMID: 24479980.

30. del Pilar Martin M, Cravens PD, Winger R, et al. 2008; Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 65:1596–1603. DOI: 10.1001/archneur.65.12.noc80051. PMID: 18852339.

31. Kleinschmidt-DeMasters BK, Tyler KL. 2005; Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 353:369–374. DOI: 10.1056/NEJMoa051782. PMID: 15947079.

32. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. 2005; Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 353:375–381. DOI: 10.1056/NEJMoa051847. PMID: 15947078.

33. Döring A, Pfeiffer F, Meier M, et al. 2011; TET inducible expression of the α4β7-integrin ligand MAdCAM-1 on the blood-brain barrier does not influence the immunopathogenesis of experimental autoimmune encephalomyelitis. Eur J Immunol. 41:813–821. DOI: 10.1002/eji.201040912. PMID: 21341265.

34. Feagan BG, Rubin DT, Danese S, et al. 2017; Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 15:229–239.e5. DOI: 10.1016/j.cgh.2016.08.044. PMID: 27639327.

35. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. 2019; Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 381:1215–1226. DOI: 10.1056/NEJMoa1905725. PMID: 31553834.

36. Loftus EV Jr, Colombel JF, Feagan BG, et al. 2017; Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 11:400–411.

37. Vermeire S, Loftus EV Jr, Colombel JF, et al. 2017; Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis. 11:412–424.

38. Noman M, Ferrante M, Bisschops R, et al. 2017; Vedolizumab induces long-term mucosal healing in patients with Crohn's disease and ulcerative colitis. J Crohns Colitis. 11:1085–1089. DOI: 10.1093/ecco-jcc/jjx048. PMID: 28369329.

39. Löwenberg M, Vermeire S, Mostafavi N, et al. 2019; Vedolizumab induces endoscopic and histologic remission in patients with Crohn's disease. Gastroenterology. 157:997–1006.e6. DOI: 10.1053/j.gastro.2019.05.067. PMID: 31175865.

40. Dulai PS, Singh S, Jiang X, et al. 2016; The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY consortium. Am J Gastroenterol. 111:1147–1155. DOI: 10.1038/ajg.2016.236. PMID: 27296941.

41. Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. 2016; Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 14:1593–1601.e2.

42. Vickers AD, Ainsworth C, Mody R, et al. 2016; Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS One. 11:e0165435. DOI: 10.1371/journal.pone.0165435. PMID: 27776175. PMCID: PMC5077077.

43. Colombel JF, Sands BE, Rutgeerts P, et al. 2017; The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66:839–851. DOI: 10.1136/gutjnl-2015-311079. PMID: 26893500. PMCID: PMC5531223.

44. Amiot A, Serrero M, Peyrin-Biroulet L, et al. 2017; One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 46:310–321. DOI: 10.1111/apt.14167. PMID: 28593685.

45. Dulai PS, Singh S, Vande Casteele N, et al. 2020; Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 18:2952–2961.e8. DOI: 10.1016/j.cgh.2020.02.010. PMID: 32062041. PMCID: PMC7899124.

46. Dulai PS, Boland BS, Singh S, et al. 2018; Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's dIsease. Gastroenterology. 155:687–695.e10. DOI: 10.1053/j.gastro.2018.05.039. PMID: 29857091. PMCID: PMC6419724.

47. Bertani L, Caviglia GP, Antonioli L, et al. 2020; Serum interleukin-6 and-8 as predictors of response to vedolizumab in inflammatory bowel diseases. J Clin Med. 9:1323. DOI: 10.3390/jcm9051323. PMID: 32370274. PMCID: PMC7290461.

48. Fuchs F, Schillinger D, Atreya R, et al. 2017; Clinical response to vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles. Front Immunol. 8:764. DOI: 10.3389/fimmu.2017.00764. PMID: 28717358. PMCID: PMC5495081.

49. Loftus EV Jr, Feagan BG, Panaccione R, et al. 2020; Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 52:1353–1365. DOI: 10.1111/apt.16060. PMID: 32876349. PMCID: PMC7540482.

50. Sandborn WJ, Baert F, Danese S, et al. 2020; Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 158:562–572. e12. DOI: 10.1053/j.gastro.2019.08.027. PMID: 31470005.

51. Vermeire S, D'Haens G, Baert F, et al. 2022; Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 16:27–38. DOI: 10.1093/ecco-jcc/jjab133. PMID: 34402887. PMCID: PMC8797168.

52. Sekhri S, Yarur AJ. 2022; Integrating new and emerging therapies into inflammatory bowel disease clinical practice. Curr Opin Gastroenterol. 38:328–336. DOI: 10.1097/MOG.0000000000000851. PMID: 35762692.

53. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR. 2007; Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol. 179:845–853. DOI: 10.4049/jimmunol.179.2.845. PMID: 17617575.

54. Danese S, Colombel JF, Lukas M, et al. 2022; Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 7:118–127. DOI: 10.1016/S2468-1253(21)00294-6. PMID: 34798038.

55. Vermeire S, Lakatos PL, Ritter T, et al. 2022; Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 7:28–37. DOI: 10.1016/S2468-1253(21)00295-8. PMID: 34798037.

56. Peyrin-Biroulet L, Rubin DT, Feagan BG, et al. 2017; LB02 Etrolizumab induction therapy improved endoscopic score, patient- reported outcomes, and inflammatory biomarkers in patients with moderate to severe UC who had failed the antagonist therapy: results from the HICKORY open-label induction (OLI) trial. United European Gastroenterol J. 5:1138–1139.

57. Pullen N, Molloy E, Carter D, et al. 2009; Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol. 157:281–293. DOI: 10.1111/j.1476-5381.2009.00137.x. PMID: 19366349. PMCID: PMC2697799.

58. D'Haens G, Vermeire S, Vogelsang H, et al. 2018; Effect of PF-00547659 on central nervous system immune surveillance and circulating β7+ T cells in Crohn's disease: report of the TOSCA study. J Crohns Colitis. 12:188–196. DOI: 10.1093/ecco-jcc/jjx128. PMID: 28961770. PMCID: PMC5881743.

59. Pan WJ, Hsu H, Rees WA, et al. 2013; Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 169:51–68. DOI: 10.1111/bph.12134. PMID: 23425116. PMCID: PMC3632238.

60. Pan WJ, Köck K, Rees WA, et al. 2014; Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol. 78:1315–1333. DOI: 10.1111/bcp.12418. PMID: 24803302. PMCID: PMC4256621.

61. Lamb CA, O'Byrne S, Keir ME, Butcher EC. 2018; Gut-selective integrin-targeted therapies for inflammatory bowel disease. J Crohns Colitis. 12(suppl_2):S653–S668. DOI: 10.1093/ecco-jcc/jjy060. PMID: 29767705.

62. Sandborn WJ, Cyrille M, Berner Hansen M, et al. 2017; Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease. J Crohns Colitis. 11(suppl_1):S22–S23. DOI: 10.1093/ecco-jcc/jjx002.034.

63. Mattheakis L, Fosser C, Saralaya R, et al. 2017; P113 Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients. J Crohns Colitis. 11(Suppl 1):S132–S133. DOI: 10.1093/ecco-jcc/jjx002.239.

64. Mattheakis L, Bhandari A, Bai L, et al. 2016; P-126 PTG-100, an oral peptide antagonist of integrin α4β7 that alters trafficking of gut homing T cells in preclinical animal models. Inflamm Bowel Dis. 22:S48. DOI: 10.1097/01.MIB.0000480232.55276.b3.

65. Sugiura T, Kageyama S, Andou A, et al. 2013; Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 7:e533–e542. DOI: 10.1016/j.crohns.2013.03.014. PMID: 23623333.

66. Yoshimura N, Watanabe M, Motoya S, et al. 2015; Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 149:1775–1783.e2. DOI: 10.1053/j.gastro.2015.08.044. PMID: 26327130.

67. Bloomgren G, Richman S, Hotermans C, et al. 2012; Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 366:1870–1880. DOI: 10.1056/NEJMoa1107829. PMID: 22591293.

68. Takazoe M, Watanabe M, Kawaguchi T, et al. 2009; S1066 oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease - a randomized, double-blind, placebo-controlled trial. 136(5 Suppl 1):A–181. DOI: 10.1016/S0016-5085(09)60816-7.